NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
6 trialsNCT04872608 2023-04-28
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT04585724 2021-10-18
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Emory University
Phase 1 Withdrawn
NCT04498520 2021-05-18
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT04220476 2020-09-21
CIMER
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT03377101 2018-08-14
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn